Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson’s disease: a pilot study.
Asako Yoritaka, Yasuko Kobayashi, Tetsuo Hayashi, Shinji Saiki, Nobutaka Hattori · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 20 participants, this pilot study revealed that the inhalation of molecular hydrogen gas was safe, but did not show any beneficial effects in patients with PD. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 20 participants. This pilot study revealed that the inhalation of molecular hydrogen gas was safe, but did not show any beneficial effects in patients with PD.
What the Researchers Studied
The researchers studied 20 participants. The study used a placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 16 weeks. This pilot study revealed that the inhalation of molecular hydrogen gas was safe, but did not show any beneficial effects in patients with PD.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 20 participants. The reported sample size was 20. The study used a placebo-controlled human clinical trial. The hydrogen delivery method was inhaled hydrogen gas. The reported treatment duration was 16 weeks.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.